Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amgen Plans Antibody Plant In Singapore

by Rick Mullin
January 28, 2013 | A version of this story appeared in Volume 91, Issue 4

Amgen plans to build a $200 million manufacturing facility in the Tuas Biomedical Park in Singapore. The project, which will take several years to complete, will expand Amgen’s manufacturing capacity for monoclonal antibodies. Construction is expected to begin later this year. “Singapore is an ideal location to further our manufacturing efforts,” says Madhu Balachandran, Amgen’s executive vice president of operations.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.